Next level opportunities for developing physician relationships across pharma's business Digital technology has transformed pharma's communications with often difficult to engage physicians. But merely having a suite of...

Injectables and implantables are key to advancing patient centricity and adherence The development of controlled and prolonged release injectable and implantable drugs has seen huge leaps forward in recent years...

As the biosimilar sector matures, what are the key issues that are shaping commercial strategies? As physician and payer confidence in the use of biosimilars grows, US and European companies are having to rethink their...

Pharma challenged to rethink its market access strategies While the promise of cell and gene therapy (C&GT) to deliver enduring or even curative treatments is welcomed there is no long-term market experience and...

Which digital health technologies are exciting payers? How and where can digital health technology improve patient outcomes and save payers money? Across the digital health field there are hundreds of applications...

How well has RWE integrated into Medical Affairs—and should more be done? Payers and other stakeholders increasingly expect to see real world evidence (RWE) to support their decision making. Since being added to...

What do you need to do to get payer support for companion diagnostics and biomarkers? The investment decisions made by the biggest players in core disease areas drive market trends—so it's crucial to understand...

Health insurance: how to thrive in an increasingly digital health world Health insurers are being challenged to develop a portfolio of digital services with limited knowledge of their effectiveness and at a considerable...